Journal of Clinical Oncology
Articles in this Issue
Prevalence of cytopenic myelofibrosis in the United States.
e18575 Background: Among patient (pts) with myelofibrosis (MF), cytopenias (anemia or thrombocytopenia) are a marker of advanced disease, associated with...
Impact of sociodemographic and clinical factors on time to treatment initiation in adult soft tissue sarcomas: An NCDB analysis.
e23548 Background: Soft tissue sarcomas (STS) are a heterogeneous group of cancers that often require complex, multidisciplinary care. Delays in initiatin...
Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.
7026 Background: CAR T cell therapies have shown remarkable efficacy in B-cell NHL. Here, we report CRS and ICANS timing in 1579 patients (pt) treated wit...
Exploring potential biomarkers for FOLFIRI plus aflibercept as second-line treatment in patients with metastatic colorectal cancer.
e15563 Background: FOLFIRI plus aflibercept (AFL) or bevacizumab (BEV) are significant therapeutic options for patients with metastatic colorectal cancer...
Association of GLP1-RA with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: Biochemical and preclinical evidences.
e24012 Background: Recent meta analyzes have highlighted the key role of oxLDL in cardiovascular risk in patients with/without cancer through the stimulat...
Long-term outcomes in GIST Trial 13-162: Phase II study of imatinib in combination with binimetinib in untreated patients with advanced gastrointestinal stromal tumor (GIST).
11527 Background: ETV1 and KIT are lineage-specific master transcriptional and signaling survival factors in GIST. Dual lineage targeting of ETV1 by binim...
Neuromorphological effects of simultaneous exercise during neo-/adjuvant chemotherapy in breast cancer patients: The Exercise Cancer and Cognition (ECCO) study.
544 Background: Cancer-Related Cognitive Impairment (CRCI) is commonly experienced by breast cancer patients, often linked to chemotherapy. It manifests a...
Effect of EDIL3+ CAFs on lymph node metastasis through disruption of lymphatic endothelial barriers in breast cancer.
e13029 Background: Axillary lymph node (LN) metastasis is the most common metastatic route in breast cancer and a critical prognostic indicator. While pre...
Accurate differentiation of malignant and benign gastric lesions using cell-free DNA biomarkers.
3047 Background: Early detection of gastric cancer is challenging due to the invasive nature of current diagnostic methods and the difficulty in distingui...
IDOV-Safe: An intravenously deliverable oncolytic vaccinia virus for solid tumors refractory to standard of care—preliminary results from the pMMR/MSS CRC cohort.
e15556 Background: Metastatic pMMR/MSS colorectal cancer (CRC) remains challenging to treat following progression on oxaliplatin- and irinotecan- based th...
Dedicated resources for veteran clinical trial participation: The Prostate Cancer Analysis for Therapy Choice (PATCH) program.
5040 Background: The Veterans Affairs (VA) hospital system is the most extensive integrated healthcare system in the United States. It serves 9.1 million...
EGL-121, a first-in-human phase 1/2 trial of EGL-001 in adult patients with selected advanced and/or metastatic solid tumors.
TPS2672 Background: Regulatory T cells (Tregs) play a key role in the resistance to immune checkpoint inhibitors therapy (ICI). Disarming Tregs could ther...
GUIDE-G: An artificial intelligence-powered platform for dynamic NCCN guideline visualization in breast cancer (BC).
9027 Background: Breast cancer (BC) management has evolved rapidly, with 17 FDA approvals in the past five years. Increasing complexity in NCCN guidelines...
Frequency and spectrum of BRCA pathogenic/likely pathogenic variants in the Hispanic population of south Florida: A retrospective analysis.
10579 Background: The genetic landscape of hereditary breast and ovarian cancer in diverse populations remains underexplored, particularly within Hispanic...
Prognostic profiling of hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors beyond progression (BP): A synthetic control arm biomarker analysis.
e13068 Background: Second-line treatment for HR+/HER2- MBC is evolving, requiring integration of new treatment strategies such as CDK4/6i BP novel targete...
Molecular docking investigating methotrexate as a potential target for addressing cardiovascular disease risk associated with cancer.
e24000 Background: Cardiovascular Disease (CVD) and Cancer are recognized as the leading cause of mortality worldwide, and adult cancer survivors have a 4...
A randomized phase III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for participants with painful non-spine bone metastases (NCT06391242).
TPS12141 Background: Stereotactic body radiotherapy (SBRT) is efficacious in the treatment of painful spinal metastases [1]. Data are required regarding t...
Efficacy of anti-VEGF & anti-EGFRs in microsatellite instable (MSI-H) metastatic colorectal cancer, Turkish Oncology Group (TOG) study.
e15507 Background: Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) CRC tumors constitute of 5% of mCRC. Immunotherapy is a new st...
Development and clinical validation of a cell-free DNA methylation sequencing test for multi-cancer early detection.
10537 Background: Achieving robust early-stage sensitivity in multi-cancer early detection (MCED) poses challenges, relying on large cohorts of early-stag...
Improving the collection of patient-reported outcomes: Key factors influencing completion and drop-off rates.
e23204 Background: Incorporating patient-reported outcomes (PROs) into healthcare processes can improve patient engagement and inform clinical decision-ma...
First-in-human study of <sup>177</sup> Lu-JH020002 in patients with metastatic castration-resistant prostate cancer.
5055 Background: 177 Lu-JH020002 is a novel radioligand therapy that delivers beta-particle radiation to PSMA-expressing tumor cells and the s...
Implementation of a breast cancer survivorship needs assessment tool, an ASCO Quality Training Program initiative.
e23232 Background: The 2015 ASCO Breast Cancer Survivorship Guidelines recommend needs assessment, although real-world implementation data are limited. To...
Perception and concerns of the hematology and oncology (HemOnc) workforce about artificial intelligence (AI) in clinical practice (CliPr) and medical education (MedED).
9002 Background: The field of AI is rapidly evolving. With recent development of more user-friendly AI software, its integration into healthcare across di...
Cost-effectiveness analysis of population-based screening for 6-gene panel testing for hereditary breast and ovarian cancer.
10541 Background: Genetic testing for hereditary breast and ovarian cancer (HBOC) has relied on clinical and family history criteria. This approach, has b...
Patient-reported communication and satisfaction in breast cancer: Does doctor-patient identity concordance matter?
11071 Background: Effective communication is a key element in patient engagement, adherence, and satisfaction. Prior research has shown that doctor-patien...